Results 1 to 10 of about 168,876 (247)

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1

Frontiers in Oncology, 2022
The breakthrough in the discovery of immune checkpoint PD-1/PD-L1 inhibitors, such as the series of Bristol Myers Squibb synthetic compounds, boosted the research of small molecules with blockade effects on the interaction of PD-1/PD-L1.
Huifang Li, Navindra P. Seeram, Chang Liu, Hang Ma   +3 more
doaj   +1 more source

Programmed Cell Death Ligand 1 Is Enriched in Mammary Stem Cells and Promotes Mammary Development and Regeneration

Frontiers in Cell and Developmental Biology, 2021
Programmed cell death ligand 1 (PD-L1) is widely expressed in a variety of human tumors, and inhibition of the PD-L1/PD-1 pathway represents one of the most promising therapy for many types of cancer.
Ruirui Wang, Fujing Huang, Wei Wei, Yu Zhou, Zi Ye, Liya Yu, Junyuan Hu, Cheguo Cai, Cheguo Cai   +8 more
doaj   +1 more source

Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma

Biology, 2021
Programmed cell death ligand 1 (PD-L1) inhibitors are commonly used in treating advanced-stage urothelial carcinoma (UC). Therefore, this study evaluated the relationship between PD-L1 expression in circulating tumor cells (CTCs) and treatment response ...
Pei-Jhang Chiang, Ting Xu, Tai-Lung Cha, Yi-Ta Tsai, Shu-Yu Liu, Sheng-Tang Wu, En Meng, Chih-Wei Tsao, Chien-Chang Kao, Chin-Li Chen, Guang-Huan Sun, Dah-Shyong Yu, Sun-Yran Chang, Ming-Hsin Yang   +13 more
doaj   +1 more source

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential

Frontiers in Immunology, 2020
PD-1/PD-L1 immune checkpoint inhibitors show potential for cervical cancer treatment. However, low response rates suggest that patient selection based on PD-L1 protein expression is not optimal.
Jossie Rotman, Jossie Rotman, Leontine A. S. den Otter, Maaike C. G. Bleeker, Sanne S. Samuels, A. Marijne Heeren, Margaretha G. M. Roemer, Gemma G. Kenter, Gemma G. Kenter, Henry J. M. A. A. Zijlmans, Nienke E. van Trommel, Tanja D. de Gruijl, Ekaterina S. Jordanova, Ekaterina S. Jordanova   +13 more
doaj   +1 more source

PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain

Nature Communications, 2021
The cytoplasmic domain of PD-L1 (PD-L1-CD) is involved in regulating PD-L1 stability and degradation. Here the authors show that membrane binding of PD-L1-CD mediates the cellular levels of PD-L1, while metformin can disrupt the interaction between PD-L1-
Maorong Wen, Yunlei Cao, Bin Wu, Taoran Xiao, Ruiyu Cao, Qian Wang, Xiwei Liu, Hongjuan Xue, Yang Yu, Jialing Lin, Chenqi Xu, Jie Xu, Bo OuYang   +12 more
doaj   +1 more source

Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer

JTO Clinical and Research Reports, 2022
Introduction: Programmed death-ligand 1 (PD-L1) expression determined by immunohistochemistry is the most widely used biomarker for predicting response to immune checkpoint inhibitors.
Yi-Chen Yeh, MD, Hsiu-Hsun Ma, MS, Ping-Yuan Chu, MS, Hsiang-Ling Ho, PhD, Teh-Ying Chou, MD, PhD   +4 more
doaj   +1 more source

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.

PLoS ONE, 2020
Programmed death-1 (PD-1) is an immunoinhibitory receptor expressed on lymphocytes. Interaction of PD-1 with its ligand PD-ligand 1 (PD-L1) delivers inhibitory signals and impairs proliferation, cytokine production, and cytotoxicity of T cells.
Otgontuya Ganbaatar, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Naoya Maekawa, Erina Minato, Atsushi Kobayashi, Ryo Ando, Nobuya Sasaki, Daisuke Miyakoshi, Osamu Ichii, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi   +14 more
doaj   +1 more source

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

EJNMMI Research, 2020
Background Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors.
Sheng Zhao, Wenbin Pan, Huijie Jiang, Rongjun Zhang, Hao Jiang, Zonghui Liang, Hongbo Hu   +6 more
doaj   +1 more source

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Biomedicines, 2021
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu, Wei Li, Ken H. Young, Yong Li   +3 more
doaj   +1 more source

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export

OncoImmunology, 2020
Therapeutic monoclonal antibodies against the PD-L1/PD-1 (programmed death ligand-1/programmed cell death protein-1) axis have achieved great successes in cancer treatments, but the development of small-molecule immunomodulators of the pathway has lagged
Fang-Fang Chen, Zheng Li, Dawei Ma, Qiang Yu   +3 more
doaj   +1 more source